HRP20120256T1 - Inhibitori kinaza i postupci njihove upotrebe - Google Patents
Inhibitori kinaza i postupci njihove upotrebe Download PDFInfo
- Publication number
- HRP20120256T1 HRP20120256T1 HR20120256T HRP20120256T HRP20120256T1 HR P20120256 T1 HRP20120256 T1 HR P20120256T1 HR 20120256 T HR20120256 T HR 20120256T HR P20120256 T HRP20120256 T HR P20120256T HR P20120256 T1 HRP20120256 T1 HR P20120256T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- formula
- image
- pharmaceutically acceptable
- disease
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 5
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 17
- 150000003839 salts Chemical class 0.000 claims abstract 7
- 108091000080 Phosphotransferase Proteins 0.000 claims abstract 5
- 230000001404 mediated effect Effects 0.000 claims abstract 5
- 102000020233 phosphotransferase Human genes 0.000 claims abstract 5
- 239000000651 prodrug Substances 0.000 claims abstract 3
- 229940002612 prodrug Drugs 0.000 claims abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- UTVBCYCHQGKWJM-UHFFFAOYSA-N 2-[5-[2-[[[5-tert-butyl-2-(4-methylphenyl)pyrazol-3-yl]carbamoylamino]methyl]-4-fluorophenoxy]indazol-1-yl]ethyl dihydrogen phosphate Chemical compound C1=CC(C)=CC=C1N1C(NC(=O)NCC=2C(=CC=C(F)C=2)OC=2C=C3C=NN(CCOP(O)(O)=O)C3=CC=2)=CC(C(C)(C)C)=N1 UTVBCYCHQGKWJM-UHFFFAOYSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000020084 Bone disease Diseases 0.000 claims 2
- 208000035473 Communicable disease Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 125000003158 alcohol group Chemical group 0.000 claims 2
- 230000001066 destructive effect Effects 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- QDWJUBJKEHXSMT-UHFFFAOYSA-N boranylidynenickel Chemical compound [Ni]#B QDWJUBJKEHXSMT-UHFFFAOYSA-N 0.000 claims 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 239000012948 isocyanate Substances 0.000 claims 1
- 150000002513 isocyanates Chemical class 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76371206P | 2006-01-31 | 2006-01-31 | |
PCT/US2007/002272 WO2007089646A1 (en) | 2006-01-31 | 2007-01-26 | Kinase inhibitors and methods of use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20120256T1 true HRP20120256T1 (hr) | 2012-04-30 |
Family
ID=38037453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20120256T HRP20120256T1 (hr) | 2006-01-31 | 2012-03-21 | Inhibitori kinaza i postupci njihove upotrebe |
Country Status (27)
Country | Link |
---|---|
US (2) | US8044083B2 (zh) |
EP (1) | EP1981851B1 (zh) |
JP (1) | JP5131990B2 (zh) |
KR (1) | KR101357465B1 (zh) |
CN (1) | CN101415685B (zh) |
AT (1) | ATE542800T1 (zh) |
AU (1) | AU2007210073B2 (zh) |
BR (1) | BRPI0707401B8 (zh) |
CA (1) | CA2635813C (zh) |
CY (1) | CY1112770T1 (zh) |
DK (1) | DK1981851T3 (zh) |
ES (1) | ES2379656T3 (zh) |
HK (1) | HK1123548A1 (zh) |
HR (1) | HRP20120256T1 (zh) |
IL (3) | IL192949A (zh) |
MY (1) | MY151835A (zh) |
NZ (1) | NZ570846A (zh) |
PL (1) | PL1981851T3 (zh) |
PT (1) | PT1981851E (zh) |
RS (1) | RS52298B (zh) |
RU (1) | RU2442777C2 (zh) |
SG (1) | SG175599A1 (zh) |
SI (1) | SI1981851T1 (zh) |
TW (1) | TWI388557B (zh) |
UA (1) | UA94733C2 (zh) |
WO (1) | WO2007089646A1 (zh) |
ZA (1) | ZA200806507B (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
PT1981851E (pt) | 2006-01-31 | 2012-04-13 | Array Biopharma Inc | Inibidores de cinase e processos para a sua utilização |
WO2009015000A1 (en) * | 2007-07-25 | 2009-01-29 | Array Biopharma Inc. | Pyrazole urea derivatives used as kinase inhibitors |
EP2196461A1 (de) | 2008-12-15 | 2010-06-16 | Bayer CropScience AG | 4-Amino-1,2,3-benzoxathiazin-Derivate als Pestizide |
PL2712358T3 (pl) | 2011-05-13 | 2017-05-31 | Array Biopharma, Inc. | Związki mocznika pirolidynowego, tiomocznika pirolidynowego oraz guanidyny pirolidynowej jako inhibitory kinazy trka |
CN104245677B (zh) * | 2012-03-01 | 2017-05-10 | 阵列生物制药公司 | 1‑(3‑叔丁基‑1‑对甲苯基‑1h‑吡唑‑5‑基)‑3‑(5‑氟‑2‑(1‑(2‑羟乙基)‑1h‑吲唑‑5‑基氧基)苯甲基)脲盐酸盐的晶形 |
WO2014134313A1 (en) | 2013-02-27 | 2014-09-04 | Array Biopharma Inc. | Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof |
DK3691620T3 (da) | 2017-10-05 | 2022-10-03 | Fulcrum Therapeutics Inc | P38-kinaseinhibitor reducerer dux4- og downstream-gen-ekspression til behandling af fshd |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
JP7028977B2 (ja) | 2017-12-13 | 2022-03-02 | ジェンフリート セラピューティクス(シャンハイ)インコーポレイテッド | TGF-βRI阻害剤の結晶形、塩形態及びその製造方法 |
WO2023084459A1 (en) | 2021-11-15 | 2023-05-19 | Pfizer Inc. | Methods of treating sars-cov-2 |
Family Cites Families (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3755332A (en) * | 1971-07-01 | 1973-08-28 | Ciba Geigy Corp | Substituted 4 indazolaminoquinolines |
JPS5998060A (ja) | 1982-11-27 | 1984-06-06 | Fujisawa Pharmaceut Co Ltd | インダゾ−ル誘導体、その製造法および農薬 |
US4571255A (en) * | 1983-12-29 | 1986-02-18 | Ppg Industries, Inc. | Subsituted phenoxybenzisoxazole herbicides |
GB8524157D0 (en) * | 1984-10-19 | 1985-11-06 | Ici America Inc | Heterocyclic amides |
SU1545940A3 (ru) | 1984-10-19 | 1990-02-23 | Ай-Си-Ай Америказ Инк (Фирма) | Способ получени гетероциклических кислот или их солей |
US5234942A (en) * | 1984-10-19 | 1993-08-10 | Ici Americas Inc. | Heterocyclic amides and leucotriene antagonistic use thereof |
PL265549A1 (en) | 1985-03-26 | 1988-09-01 | The method of manufacture of new heterocyclic amides | |
JPS6368568A (ja) | 1986-09-10 | 1988-03-28 | Otsuka Pharmaceut Factory Inc | p−アミノフエノ−ル誘導体 |
NZ224714A (en) | 1987-06-01 | 1990-03-27 | Janssen Pharmaceutica Nv | Substituted benzotriazole derivatives and pharmaceutical compositions |
IE910278A1 (en) | 1990-02-16 | 1991-08-28 | Ici Plc | Heterocyclic compounds |
JPH06503095A (ja) | 1991-05-29 | 1994-04-07 | ファイザー・インコーポレーテッド | 三環式ポリヒドロキシ系のチロシンキナーゼ阻害薬 |
EP0606489A4 (en) * | 1992-07-03 | 1995-01-25 | Kumiai Chemical Industry Co | CONDENSED HETEROCYCLIC DERIVATIVE AND HERBICIDE. |
EP0684235A1 (en) | 1994-05-27 | 1995-11-29 | Mochida Pharmaceutical Co., Ltd. | Novel azolyl methyl phenyl derivatives having aromatase inhibitory activity |
US6083949A (en) * | 1995-10-06 | 2000-07-04 | Merck & Co., Inc. | Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
KR19990064117A (ko) | 1995-10-06 | 1999-07-26 | 폴락 돈나 엘. | 항암 활성과 사이토킨 억제 활성을 갖는 치환된 이미다졸 |
BR9712005A (pt) | 1996-09-04 | 1999-08-24 | Pfizer | Derivados de indazol e seus usos como inibidores de fosfodiesterase (pde) tipo IV e produ-Æo do fator de necrose de tumor (tnf) |
DE69733825T2 (de) | 1996-09-25 | 2006-06-08 | Astrazeneca Ab | Chinolin-derivate die den effekt von wachstumsfaktoren wie vegf vezögern |
US5932570A (en) * | 1996-11-08 | 1999-08-03 | Dupont Pharmaceuticals Company | 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as HIV protease inhibitors |
US6218386B1 (en) * | 1996-11-08 | 2001-04-17 | Dupont Pharmaceuticals | A1-(3-aminoindazol-5-yl)-3 butyl-cyclic urea useful as a HIV protease inhibitor |
WO1998020008A1 (en) | 1996-11-08 | 1998-05-14 | Du Pont Pharmaceuticals Company | 1-(3-aminoindazol-5-yl)-3-phenylmethyl-cyclic ureas useful as hiv protease inhibitors |
US5945418A (en) * | 1996-12-18 | 1999-08-31 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
UA73073C2 (uk) | 1997-04-03 | 2005-06-15 | Уайт Холдінгз Корпорейшн | Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція |
AU7138298A (en) * | 1997-04-24 | 1998-11-13 | Ortho-Mcneil Corporation, Inc. | Substituted imidazoles useful in the treatment of inflammatory diseases |
WO1998052941A1 (en) * | 1997-05-22 | 1998-11-26 | G.D. Searle And Co. | PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS |
US6093742A (en) * | 1997-06-27 | 2000-07-25 | Vertex Pharmaceuticals, Inc. | Inhibitors of p38 |
US6297239B1 (en) * | 1997-10-08 | 2001-10-02 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
TR200001079T2 (tr) * | 1997-10-20 | 2000-07-21 | F.Hoffmann-La Roche Ag | Bisiklik kinaz inhibitörleri. |
WO1999023091A1 (en) * | 1997-11-03 | 1999-05-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
WO1999023076A1 (en) | 1997-11-04 | 1999-05-14 | Pfizer Products Inc. | Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors |
US6329412B1 (en) * | 1997-11-04 | 2001-12-11 | Pfizer Inc | Bisamidine compounds as antiproliferative agents |
ID23921A (id) | 1997-11-04 | 2000-05-25 | Pfizer Prod Inc | Penggantian indazola bioisostere katekol pada senyawa-senyawa aktif untuk terapi |
US6589954B1 (en) * | 1998-05-22 | 2003-07-08 | Scios, Inc. | Compounds and methods to treat cardiac failure and other disorders |
GB9820767D0 (en) | 1998-09-23 | 1998-11-18 | Cerebrus Ltd | Chemical compounds VIII |
UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
CA2360934A1 (en) * | 1999-02-22 | 2000-08-31 | Lin-Hua Zhang | Polycyclo heterocyclic derivatives as antiinflammatory agents |
DK1165516T3 (da) * | 1999-03-12 | 2005-01-31 | Boehringer Ingelheim Pharma | Heterocyklisk urinstof og beslægtede forbindelser, der er nyttige som antiinflammatoriske midler |
ATE309237T1 (de) * | 1999-03-12 | 2005-11-15 | Boehringer Ingelheim Pharma | Aromatische heterozyklische verbindungen als antientzündungwirkstoffe |
EP1165096B1 (en) * | 1999-03-29 | 2009-09-09 | Shire Canada Inc. | Use of cytidine derivatives for the treatment of leukaemia |
WO2000059930A1 (en) | 1999-04-05 | 2000-10-12 | Merck & Co., Inc. | A method of treating cancer |
NZ514576A (en) | 1999-04-21 | 2004-02-27 | Wyeth Corp | Substituted 3-cyano-[1.7], [1.5], and [1.8]- naphthyridine inhibitors of tyrosine kinases |
US6355636B1 (en) * | 1999-04-21 | 2002-03-12 | American Cyanamid Company | Substituted 3-cyano-[1.7],[1.5], and [1.8] naphthyridine inhibitors of tyrosine kinases |
ATE376547T1 (de) | 1999-05-21 | 2007-11-15 | Scios Inc | Derivate des indol-typs als p38 kinase inhibitoren |
TWI262914B (en) * | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
DE60024830T2 (de) * | 1999-07-09 | 2006-06-14 | Boehringer Ingelheim Pharma | Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen |
JP2003523952A (ja) * | 1999-11-27 | 2003-08-12 | ドン ファ ファーマシューティカル インダストリアル カンパニー リミテッド | 新規な3−ニトロピリジン誘導体及び該誘導体を含む製薬組成物 |
WO2001038306A1 (en) | 1999-11-27 | 2001-05-31 | Dong Wha Pharm. Ind. Co., Ltd | Novel 3-nitropyridine derivatives and the pharmaceutical compositions containing said derivatives |
AU4890301A (en) | 2000-04-17 | 2001-10-30 | Dong Wha Pharmaceutical Industrial Co., Ltd. | 6-methylnicotinamide derivatives as antiviral agents |
AU2002226911A1 (en) | 2000-11-20 | 2002-06-03 | Scios Inc. | Indol derivative and their use as inhibitors of p38 kinase |
US7102009B2 (en) | 2001-01-12 | 2006-09-05 | Amgen Inc. | Substituted amine derivatives and methods of use |
US7105682B2 (en) | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
TW593278B (en) | 2001-01-23 | 2004-06-21 | Wyeth Corp | 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
HUP0303415A2 (hu) * | 2001-03-09 | 2004-01-28 | Pfizer Products Inc. | Triazolopiridinek, mint gyulladásgátló anyagok és ezeket tartalmazó gyógyszerkészítmények |
WO2002100833A1 (fr) | 2001-06-12 | 2002-12-19 | Sumitomo Pharmaceuticals Company, Limited | Inhibiteurs de rho kinase |
ATE495741T1 (de) * | 2001-09-26 | 2011-02-15 | Pfizer Italia Srl | Aminoindazolderivate mit kinaseinhibierender wirkung, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen |
WO2003032989A1 (en) | 2001-10-18 | 2003-04-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors |
WO2003051847A1 (en) | 2001-12-19 | 2003-06-26 | Smithkline Beecham P.L.C. | (1-h-indazol-3-yl) -amide derivatives as gsk-3 inhibitors |
DE60319066T2 (de) * | 2002-02-25 | 2009-02-26 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield | 1,4-disubstituierte benzokondensierte cycloalkyl-harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen |
FR2836915B1 (fr) | 2002-03-11 | 2008-01-11 | Aventis Pharma Sa | Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
FR2836914B1 (fr) * | 2002-03-11 | 2008-03-14 | Aventis Pharma Sa | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
WO2003087072A1 (fr) | 2002-03-29 | 2003-10-23 | Mochida Pharmaceutical Co., Ltd. | Agent therapeutique destine a des troubles endotheliaux |
AU2003256601B2 (en) | 2002-07-19 | 2009-10-29 | Memory Pharmaceuticals Corporation | 6-amino-1H-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors |
AU2003278249B8 (en) | 2002-09-05 | 2010-11-18 | Aventis Pharma S.A. | Novel aminoindazole derivatives as medicines and pharmaceutical compositions containing same |
BR0315580A (pt) | 2002-10-24 | 2005-08-30 | Merck Patent Gmbh | Derivados de metileno uréia |
CA2503646C (en) | 2002-10-28 | 2011-09-27 | Bayer Healthcare Ag | Heteroaryloxy-substituted phenylaminopyrimidines as rho-kinase inhibitors |
US7196082B2 (en) * | 2002-11-08 | 2007-03-27 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
WO2004052280A2 (en) | 2002-12-10 | 2004-06-24 | Imclone Systems Incorporated | Anti-angiogenic compounds and their use in cancer treatment |
WO2004078116A2 (en) * | 2003-03-03 | 2004-09-16 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
GB0320244D0 (en) | 2003-05-06 | 2003-10-01 | Aventis Pharma Inc | Pyrazoles as inhibitors of tumour necrosis factor |
US7129252B2 (en) * | 2003-06-16 | 2006-10-31 | Guoqing P Chen | Six membered amino-amide derivatives an angiogenisis inhibitors |
SE0301906D0 (sv) | 2003-06-26 | 2003-06-26 | Astrazeneca Ab | New compounds |
US20090048301A1 (en) * | 2003-07-09 | 2009-02-19 | Imclone Systems Incorporated | Heterocyclic compounds and their use as anticancer agents |
CN102060806A (zh) * | 2003-09-11 | 2011-05-18 | iTherX药品公司 | 细胞因子抑制剂 |
CA2547837A1 (en) | 2003-12-18 | 2005-07-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Polymorph of birb 796, a p38map kinase inhibitor |
BRPI0417714A (pt) * | 2003-12-22 | 2007-03-20 | Lilly Co Eli | composto, composição farmacêutica, e, uso de um composto |
EP1883404A4 (en) * | 2005-05-11 | 2010-03-31 | Array Biopharma Inc | P38 INHIBITORS AND METHODS OF USE |
PT1981851E (pt) | 2006-01-31 | 2012-04-13 | Array Biopharma Inc | Inibidores de cinase e processos para a sua utilização |
-
2007
- 2007-01-26 PT PT07762713T patent/PT1981851E/pt unknown
- 2007-01-26 WO PCT/US2007/002272 patent/WO2007089646A1/en active Application Filing
- 2007-01-26 PL PL07762713T patent/PL1981851T3/pl unknown
- 2007-01-26 BR BRPI0707401A patent/BRPI0707401B8/pt active IP Right Grant
- 2007-01-26 US US12/161,412 patent/US8044083B2/en active Active
- 2007-01-26 NZ NZ570846A patent/NZ570846A/en unknown
- 2007-01-26 RU RU2008135332/04A patent/RU2442777C2/ru active
- 2007-01-26 DK DK07762713.1T patent/DK1981851T3/da active
- 2007-01-26 AT AT07762713T patent/ATE542800T1/de active
- 2007-01-26 CA CA2635813A patent/CA2635813C/en active Active
- 2007-01-26 EP EP07762713A patent/EP1981851B1/en active Active
- 2007-01-26 SI SI200730895T patent/SI1981851T1/sl unknown
- 2007-01-26 CN CN2007800120196A patent/CN101415685B/zh active Active
- 2007-01-26 KR KR1020087021184A patent/KR101357465B1/ko active IP Right Grant
- 2007-01-26 SG SG2011073152A patent/SG175599A1/en unknown
- 2007-01-26 JP JP2008553277A patent/JP5131990B2/ja active Active
- 2007-01-26 MY MYPI20082836 patent/MY151835A/en unknown
- 2007-01-26 AU AU2007210073A patent/AU2007210073B2/en active Active
- 2007-01-26 UA UAA200810690A patent/UA94733C2/ru unknown
- 2007-01-26 RS RS20120119A patent/RS52298B/en unknown
- 2007-01-26 ES ES07762713T patent/ES2379656T3/es active Active
- 2007-01-30 TW TW096103341A patent/TWI388557B/zh active
-
2008
- 2008-07-22 IL IL192949A patent/IL192949A/en active IP Right Grant
- 2008-07-25 ZA ZA200806507A patent/ZA200806507B/xx unknown
-
2009
- 2009-01-23 HK HK09100807.4A patent/HK1123548A1/xx unknown
-
2011
- 2011-02-03 US US13/020,578 patent/US8039639B2/en active Active
-
2012
- 2012-03-19 CY CY20121100291T patent/CY1112770T1/el unknown
- 2012-03-21 HR HR20120256T patent/HRP20120256T1/hr unknown
- 2012-05-08 IL IL219643A patent/IL219643A/en active IP Right Grant
- 2012-05-08 IL IL219644A patent/IL219644A/en active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20120256T1 (hr) | Inhibitori kinaza i postupci njihove upotrebe | |
ECSP10010608A (es) | 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas | |
DOP2010000309A (es) | 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas | |
NO20090075L (no) | Nye CXCR2 inhibitorer | |
PE20141167A1 (es) | Piridopirazinas sustituidas como inhibidores novedosos de ptk | |
CL2012000708A1 (es) | Compuestos derivados de imidazopiridina o imidazopirimidina, inhibidores de pde10a; proceso de preparacion de dichos compuestos; composiciones farmaceuticas; y su uso para el tratamiento terapeutico y/o preventivo de trastornos psicoticos, esquizofrenia, enfermedad de alzheimer, tumores solidos, entre otras enfermedades. | |
AR087127A1 (es) | Compuestos que se unen a fxr (nr1h4) y modulan su actividad | |
MX348920B (es) | Derivados de 2-(fenil o pirid-3-il)aminopirimidina como moduladores de proteina cinasa 2 de repeticion rica en leucina (lrrk2) para el tratamiento de la enfermedad de parkinson. | |
AR063096A1 (es) | Pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina | |
JP2014511892A5 (zh) | ||
AR058780A1 (es) | Imidazopirazinas como inhibidores de quinasas dependientes de ciclina | |
MA37405A1 (fr) | Composés hétérocyclyle | |
MX2012007273A (es) | Pteridinonas como inhibidores de la quinasa tipo polo. | |
NO20090166L (no) | Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens | |
CA2725933A1 (en) | Drug combinations comprising a dgat inhibitor and a ppar-agonist | |
JP2015514060A5 (zh) | ||
MX347706B (es) | Derivados de triazol y su uso para trastornos neurologicos. | |
NO20084931L (no) | Farmasoytiske sammensetninger | |
CO6150138A2 (es) | Ciclobuten-1,2-dionas 3,4-di-sustituidas como ligandos de receptores de quimiocinas cxc | |
AR062745A1 (es) | 2-[4-(7-etil-5h-pirrolo[2,3-b]pirazin-6-il)-fenil]-propan-2-ol como inhibidor de quinasa | |
WO2012162254A8 (en) | Inhibitors of lrrk2 kinase activity | |
AR079208A2 (es) | Inhibidores de la actividad de proteina tirosina quinasa, composicion y uso de dichos inhibidores para la preparacion de un medicamento para tratar una enfermedad, trastorno o condicion oftalmica | |
UY30617A1 (es) | Derivados sustituidos del carbamato de 1-(9-{[(2r)-2-{4-hidroxi-3-[(metilsulfonil)amino]fenil}etil]amino}nonil)piperidin-4-ilo, sus sales y solvatos farmacéuticamente aceptables y aplicaciones | |
BR112014023384A2 (pt) | inibidores de bace de di-hidro-tiazina e di-hidro-oxazina espirocíclicos, e composições e usos dos mesmos | |
JP2009525330A5 (zh) |